Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance.
Funato
Tadao
T
Division of Molecular Diagnostics, Tohoku University School of Medicine, Sendai, Japan.
D000818:Animals; D001483:Base Sequence; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D020128:Inhibitory Concentration 50; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D009690:Nucleic Acid Conformation; D009841:Oligonucleotides / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D016337:RNA, Catalytic / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics
D002945:Cisplatin; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D016760:Proto-Oncogene Proteins c-fos; D016271:Proto-Oncogene Proteins c-myc; D016337:RNA, Catalytic; D018719:Erb-b2 Receptor Tyrosine Kinases